Anti-C7 antibody blocks MAC formation and prevents TRALI in mice. In a murine model of TRALI, triggered with either anti-CD36 or anti-MHC I antibodies, pretreatment with a monoclonal anti-C7 antibody inhibits MAC formation. This work sets the stage for future development of complement-based therapeutic strategies targeting C7, which could be assessed in further clinical trials, but several issues will have to be considered, including the different potential triggers inducing TRALI, targeted cells (that is, endothelial cells vs leukocytes), and other mechanisms leading to BRM release.

Anti-C7 antibody blocks MAC formation and prevents TRALI in mice. In a murine model of TRALI, triggered with either anti-CD36 or anti-MHC I antibodies, pretreatment with a monoclonal anti-C7 antibody inhibits MAC formation. This work sets the stage for future development of complement-based therapeutic strategies targeting C7, which could be assessed in further clinical trials, but several issues will have to be considered, including the different potential triggers inducing TRALI, targeted cells (that is, endothelial cells vs leukocytes), and other mechanisms leading to BRM release.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal